AUTHORS
Nuttavut Sumransub, MD, Lara Abousamra, PharmD, BCPS, BCOP2, Sandra Lee, PhD3, Corey Cutler, MD,FRCPC,MPH4, John Koreth, MD,MBBS,PhD,DPhil5, Amar Harry Kelkar, MD, MPH6, Mahasweta Gooptu, MD7, Roman Shapiro, MD8, Remy Dulery, MD, PhD9, Rizwan Romee, MD10, Sarah Nikiforow, MD, PhD11, Catherine J. Wu, MD12, Jerome Ritz, MD13, Joseph Antin, MD14, Robert J Soiffer, MD15, Vincent Ho, MD16
AFFILIATIONS
1 Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, United States, University of Minnesota, Minneapolis, Minnesota, United States
2 Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, United States
3 Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, United States
4 Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, United States
5 Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, United States
6 Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, United States
7 Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, United States
8 Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, United States
9 Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, United States
10 Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, United States
11 Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, United States
12 Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, United States
13 Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, United States
14 Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, United States
15 Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, United States
16 Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, United States
ABSTRACT
Background: Post-transplant cyclophosphamide (PTCy) at 50 mg/kg on days +3 and +4 after allograft infusion has become a standard graft-versus-host disease (GVHD) prophylaxis strategy across donor types. However, emerging evidence suggests that, while effective in reducing GVHD, PTCy may increase time to engraftment, infectious complications, and organ toxicities. Predictors of PTCy-related toxicity are lacking, and it remains unknown whether the current ideal body weight (IBW)-based dosing strategy results in overexposure and increased toxicity in leaner patients or underexposure in patients with obesity. We therefore evaluated whether the actual body weight-to-ideal body weight ratio (ABW/IBW) identifies patients at increased risk for adverse outcomes following standard-dose PTCy.
Methods: This is a retrospective cohort analysis. We analyzed 747 adults who underwent first hematopoietic cell transplantation (HCT) for hematologic malignancies between 2018 and 2024 at Dana-Farber Cancer Institute. Eligible patients received peripheral blood stem cell grafts and GVHD prophylaxis with standard-dose PTCy (IBW-based dosing of 50 mg/kg on days +3 and +4), tacrolimus, and mycophenolate mofetil, regardless of donor type or conditioning intensity. Patients were stratified by ABW/IBW ratio (<1.2 vs ≥1.2) and separately by body mass index (BMI) category (underweight/normal, overweight, and obese). Associations between categorical variables were assessed using Chi-square test and continuous measures were assessed using Wilcoxon-rank sum test. Overall survival (OS) and progression-free survival (PFS) were estimated using the Kaplan-Meier method and compared using the log-rank test. Multivariable Cox proportional hazards regression was performed to adjust for covariates. Cumulative incidence outcomes were analyzed using competing-risk methods. All analyses were reported using the 2-sided p-values.
Results: Patients with an ABW/IBW ratio <1.2 (N = 335) experienced delayed neutrophil engraftment (median 26 vs 23 days, p < 0.001) and a longer hospital length of stay (LOS) (median 27 vs 25 days, p = 0.022) compared with those with an ABW/IBW ratio ≥1.2 (N = 412). Veno-occlusive disease (VOD) occurred more frequently in the ABW/IBW <1.2 group (3.9% vs 1.5%, p = 0.059). No significant differences were observed in the incidence of acute GVHD, moderate-to-severe chronic GVHD, relapse, non-relapse mortality (NRM), or receipt of donor lymphocyte infusion (DLI) or CD34 boost. Patients with an ABW/IBW ratio <1.2 had inferior OS (p = 0.003) and numerically inferior PFS (p = 0.07). On multivariable analysis, ABW/IBW ratio ≥1.2 was associated with a lower hazard of death (HR 0.78, 95% CI 0.58–1.03; p = 0.078), with no significant association for PFS (HR 0.86, 95% CI 0.67–1.11; p = 0.244).
In analyses stratified by BMI, patients with underweight/normal BMI (N = 240) had a lower cumulative incidence of acute GVHD by day 180 than overweight (N = 256) and obese (N = 251) patients (22.5% vs 31.8% vs 31.5%, respectively, p = 0.028). Conversely, obese patients experienced faster neutrophil engraftment (median 22 vs 26 vs 26 days, p = 0.009), shorter hospital length of stay (24 vs 26 vs 27 days, p = 0.005), and a lower incidence of VOD (0.8% vs 3.1% vs 3.8%, p = 0.003) than overweight and underweight/normal BMI patients, respectively. BMI was not associated with chronic GVHD, relapse, NRM, PFS, OS, or receipt of DLI or CD34 boost. On multivariable competing-risk analysis, obesity remained independently associated with a higher incidence of acute GVHD compared with underweight/normal BMI (sHR 1.46, 95%CI (1.09, 1.95), p = 0.011).
Conclusions: An ABW/IBW ratio <1.2 was associated with delayed engraftment, prolonged hospitalization, and increased incidence of VOD, whereas obesity was associated with higher rates of acute GVHD but lower treatment-related toxicities, including faster engraftment, shorter hospitalization, and lower incidence of VOD. This pattern suggests that the current IBW-based PTCy dosing strategy may result in differential drug exposure across body weight composition, with relatively greater pharmacologic effects in patients with lower ABW/IBW and reduced effects in patients with higher ABW/IBW or obesity. Our results support prospective pharmacokinetic studies to determine whether individualized PTCy dosing or alternative dosing strategies incorporating adjusted body weight or body surface area can optimize the therapeutic index of PTCy.
DISCLOSURES
Nuttavut Sumransub, MD: No relevant conflicts of interest to declare.